

Phage composition of a fermented milk and colostrum product assessed by microbiome array; putative role of open reading frames

Stefania Pacini* and Marco Ruggiero

Silver Spring Sagl, Arzo-Mendrisio, Switzerland

*Author for correspondence: Stefania Pacini, MD, PhD. Silver Spring Sagl,
Via Raimondo Rossi 24, Arzo-Mendrisio 6864,
Switzerland.
e-mail: info@bravo-europe.com

Running title: Phages of fermented milk and colostrum

Key words: phages; milk; colostrum; RAD52; DNA repair; genome stability

Abstract

Bacteriophages (phages), Earth's most numerous biological entities, are natural constituents of alimentary matrices; in this study we describe the characterization of phage populations in a product obtained by fermentation of bovine milk and colostrum. Such characterizations were achieved using a microarray consisting of a chip covered in short DNA sequences that are specific to certain target organisms for a total of approximately 12,000 species. The only viruses evidenced by the array belonged to Siphoviridae, the largest phage family that targets bacteria and archaea. The array yielded 27 iterations corresponding to a unique target. We discuss the putative role of some open reading frames of these phages in conferring health-supporting properties.

Introduction

It is well assessed that consumption of probiotics under the form of fermented milk products such as yogurts or kefir is associated with health benefits and, in particular, with improvement of immune system function (1, 2). It appears that most healthy properties are associated with the process of fermentation rather than with the microbes themselves.

The same microbial strains that proved effective in improving the immune status of people living with HIV/AIDS, when administered as a probiotic yogurt (1), were ineffective when administered as pills containing only the encapsulated microbes and not the products of fermentation (3). According to the Authors of the latter study, "The inefficacy of the probiotic strains in preserving the immune function may be the result of using encapsulated probiotics versus the use of probiotic yogurt with the same probiotic strains in previous studies ... " (3). It can be hypothesized that microbial metabolism, during the process of fermentation, leads to the production of molecules endowed with certain healthy properties. These molecules derive from inactive precursors present in the milk before fermentation. Such an hypothesis is corroborated by evidence demonstrating that in kefir, the process of fermentation leads to production of 236 unique, newly formed peptides from the microbial metabolism of bovine milk caseins (4). Many of the newly formed peptides show health-promoting properties due to their antithrombotic, immune-modulating, antimicrobial, antioxidant, mineral binding, and opiomimetic characteristics and to their effectiveness as ACE inhibitors (4).

In addition to peptides derived from casein metabolism, in 2011 we hypothesized that beta-galactosidase and sialidase produced by lactic acid bacteria and Bifidobacteria (5, 6) were responsible for metabolism of vitamin D-binding protein (DBP) leading to production of DBP-derived macrophage activating factor (DBP-MAF) (7), a molecule endowed with a number of properties (8, 9). Consistent with this hypothesis, consumption of a product deriving from fermentation of milk and colostrum, the latter being naturally rich in DBP, for three weeks, was associated with significant improvement of immune system function (7). Based on this experience, this product of fermentation of milk and colostrum containing probiotic strains typical of yogurts and kefir, has been used in a nutritional approach for chronic conditions since 2014 (10, 11, 12).

We recently subjected this product to detailed genetic analysis using the Axiom Microbiome Array, a tool that is described as "the next generation microarray for high-throughput pathogen and microbiome analysis" (13). According to the Authors from Lawrence Livermore National Laboratory, Thermo Fisher Scientific, and Kansas State University, "The array contains probes designed to detect more than 12,000 species of viruses, bacteria, fungi, protozoa and archaea, yielding the most comprehensive microbial detection platform built to date" (13). The sensitivity of the array is such that it is able to detect pathogenic bacteria such as *Shigella* and *Aspergillus* at 100 genome copies, and viruses such as vaccinia virus DNA at 1,000 genome copies. Using this novel method to better characterize the microbial composition of the fermented product quoted above, we discovered that its biodiversity was much greater than previously anticipated, and we further documented the presence of bacteriophages (phages) belonging to the family of Siphoviridae. Such a presence did not come as a surprise since phages are the planet's most numerous biological entities and are naturally present in practically all alimentary matrices from American dairy products (14) to sweet and salted Italian baked products (15) and even to mother's breast milk (16).

In recent years, interpretation of the role of phages changed from that of "enemies" to that of "allies" in a shift of perception reminiscent of that occurred for bacteria that went from "bugs" to be eliminated at all costs, to constituents of the healthy human microbiota (17, 18). Here we describe the phage composition of this probiotic product, and discuss the putative role of the open reading frames (ORF) of some phages in conferring health supporting properties.

Materials and Methods

The Axiom Microbiome Array was performed by Eurofins Microbiology Laboratories Inc. (New Berlin Wisconsin, USA) on a commercially available product designated "Freeze-Dried Bravo - Colostrum and Probiotic Complex" (Silver Spring Sagl, Arzo-Mendrisio, Switzerland). This product derives from 48 hrs of fermentation of bovine milk and colostrum at room temperature. After 48 hrs, the product undergoes the process of freeze drying. The nutritional characteristics of the product are described in Antonucci et al. (2019) (19). The array used for this analysis is a chip covered in short DNA sequences that are specific to certain target organisms (a total of approximately 12,000 species are included).

For each target organism, the Microbiome Detection Analysis Software (MiDAS; Thermo Fisher) looks at the ratio of probes that successfully bound to their target (Probes Observed) to the total number that could potentially bind (Probes Expected) and uses this ratio to calculate the Initial Score, which is proportional to the likelihood of the target existing in the tested sample. According to Thissen et al. (13) "The initial score is the log likelihood ratio for the target being present in the sample if no other targets are present, vs no targets being present in the sample. This value gives information on what the maximum possible contribution of that target is to the holistic model of the sample, based on the probes observed when interrogating a sample with the Axiom Microbiome Array.

The conditional score gives an indicator of the actual contribution of each target to the model of the sample; it is the log likelihood for a model including the target vs a model without the target. As the conditional score takes into account the presence of other targets, it can be lower than the initial score for a given target if there are probes in common between targets." The MiDAS software is based on the Composite Likelihood Maximization Method (CLiMax) algorithm developed at Lawrence Livermore National Laboratory (13). Once the software identifies the target that it considers most likely to be present in the actual sample, the probes that correspond to the chosen target are removed and the process is repeated until adding new species no longer adds explanatory power to the software's model of the composition of the sample. The products of this iterative analysis become and are defined as "Iterations." Probes, with signal intensity above the 99th percentile of the random control probe intensities and with more than 20% of target-specific probes detected, are considered positive. In other words, a target organism is considered present when the percentage of observed probes is higher than 20% of the expected probes. In the example by Thissen et al. (13) vaccinia virus was detectable when there were 1,000 or more copies of the virus DNA in the tested sample. The number of probes observed at 1,000 copies was 78 out of 293 probes expected, or about 26%, and this value was considered positive for the presence of the virus. This assay method enables some sort of quantification; in the example quoted above, the number of probes observed at 10,000 copies of vaccinia virus was 148 out of 286 probes expected, or about 52%.

Results

The Axiom Microbiome Array did not evidence in the analyzed product any pathogenic microbes considering the sensitivity of the method as described in Thissen et al. (13). This result provides significant information on the safety of the product. This observation is also consistent with the results of the microbiological analyses for contaminants that are routinely carried out for the product in the context of the company's quality control system. The array demonstrated the presence of a very high number of targets corresponding to probiotic species. The species evidenced by the array belong to the families of Streptococcaceae, Lactobacillaceae, Leuconostocaceae, Bifidobacteriaceae, and Thermaceae. Detailed description of the prokaryotic targets identified by the array will be presented in another paper. Here, we focus our attention on double-stranded DNA viruses belonging to Siphoviridae family, the only type of viruses evidenced in the product; these represent the largest phage family that targets bacteria and archaea (20).

Table 1 shows the phage composition of the product as far as phages are concerned. The array provided 27 iterations corresponding to unique Siphoviridae targets. The phages are ordered in descending sequence with those showing the highest percentage of observed probes at the top of the list. Although the assay is not strictly quantitative, based on the results of Thissen et al. (13), it can be argued that higher percentages corresponded to higher number of viral copies.

TABLE 1

<i>Species</i>	<i>Target Description</i>	<i>Conditional Score</i>	<i>Initial Score</i>	<i>Probes Expected</i>	<i>Probes Observed</i>	<i>%</i>
Lactococcus phage BM13	Lactococcus phage BM13	175.56	175.56	67	49	73.13
Lactococcus phage P335 sensu lato	Lactococcus phage Q33	158.28	158.28	69	46	66.66
Leuconostoc phage phiLN03	Leuconostoc phage phiLN03	187.97	187.97	93	57	61.29
Leuconostoc phage phiLN04	Leuconostoc phage phiLN04	180.09	180.09	91	55	60.43
Leuconostoc phage phiLN12	Leuconostoc phage phiLN12	194	194	100	60	60
Lactococcus phage ul36	Lactococcus phage ul36	115.08	115.08	60	36	60
Lactococcus phage ul36	Lactococcus phage ul36.k1	111.18	111.18	59	35	59.32
Lactococcus phage Tuc2009	Lactococcus phage Tuc2009	115.2	115.2	65	37	56.92
Streptococcus phage TP-778L	Streptococcus phage TP-778L complete genome	129.83	129.83	74	42	56.75
Lactococcus phage ul36	Lactococcus phage ul36.k1t1	17.94	56.8	34	19	55.88
Lactococcus phage phiLC3	Lactococcus phage phiLC3	88.77	104.49	61	34	55.73
Leuconostoc phage phiLN6B	Leuconostoc phage phiLN6B	160.05	160.05	92	51	55.43
Lactococcus phage 936 sensu lato	Lactococcus phage fd13	137.07	137.07	94	48	51.06
Streptococcus phage 2972	Streptococcus phage 2972	128.48	128.48	97	47	48.45
Lactococcus phage 936 sensu lato	Lactococcus lactis phage 645	92.93	104.19	80	38	47.5
Streptococcus phage DT1	Streptococcus phage DT1	72.49	92.07	75	35	46.66
Lactococcus phage 340	Lactococcus phage 340	108.36	119.62	95	44	46.31
Lactococcus phage jm2	Lactococcus phage jm2	29.41	76.21	68	30	44.11
Lactococcus phage r1t	Lactococcus phage r1t	26.01	64.17	60	26	43.33
Lactococcus phage 936 sensu lato	Lactococcus phage CB19	54.42	96.69	95	40	42.10
Lactococcus phage jm3	Lactococcus phage jm3	16.17	70.86	74	30	40.54
Streptococcus phage Sfi11	Streptococcus phage Sfi11	18.39	86.09	94	38	40.42
Lactococcus phage 936 sensu lato	Lactococcus phage CB14	50.96	81.97	91	36	39.56
Streptococcus phage Sfi19	Streptococcus phage Sfi19	57.49	65.53	86	32	37.20
Lactococcus phage TP901-1	Lactococcus phage TP901-1	10.84	33.58	57	19	33.33
Lactococcus phage 936 sensu lato	Lactococcus phage 712	1.06	39.1	70	23	32.85
Lactococcus phage BK5-T	Lactococcus phage BK5-T	12.91	12.91	61	16	26.22

Discussion

Phages have been used for human consumption for more than 100 years (21). In 2019, the Bacteriophage for Gastrointestinal Health (PHAGE) study evaluated the safety and tolerability of supplemental phage consumption. This randomized, double-blind, placebo-controlled crossover investigation performed by Authors from prestigious US research institutions, concluded that a mixture of phages comprising Siphoviridae, the family of phages described in the present study, was safe in humans (22).

Here we describe the main features of some of the phages evidenced by the Axiom Microbiome Array in the product object of this study as they potentially relate to human health.

Lactococcus phages BM13 and Q33, the most represented in the analyzed product, have a genome showing close relatedness to phages infecting Enterococci and Clostridia, a feature that is not shared by other lactococcal P335 phages (23). The ability to infect and induce lysis of Enterococci and Clostridia may bear significant consequences for human health. Enterococci are opportunistic pathogens capable of acquiring resistance to antibiotics and have emerged as important healthcare-associated pathogens (24). A number of Clostridia is associated with human disease. For example, alterations of the gut microbiota associated with antibiotic treatment stimulate the growth of resistant strains and the onset of *Clostridium difficile* infection (25). Therefore, phages able to infect and eliminate Enterococci and Clostridia could be useful in the management of conditions associated with these pathogens, and in particular, in the presence of antibiotic-resistant strains.

Lactococcus phage ul36 encodes a protein, Sak, that is homologous to a human recombination protein, RAD52, that plays a crucial role in DNA repair, genome stability and prevention of carcinogenesis (26, 27). Such an homology is present at the amino acid, phylogenetic, functional, and structural levels and raises the possibility of a common origin with Sak being an ancestor of RAD52. A study by Authors from Canada, Switzerland and USA, demonstrated that purified Sak bound single-stranded DNA preferentially over double-stranded DNA, and promoted the renaturation of long complementary single-stranded DNAs in the context of DNA repair. Interestingly, Sak was able to self-assemble even in the absence of DNA with the formation of toroidal structures (26). This feature of Sak is interesting in the context of DNA repair, in particular, if it is compared to the self-assembly of a major protein contributing to human genome stability, the tumor suppressor protein p53, "the guardian of the - *human* - genome" (28). It was demonstrated that four p53 molecules need DNA to self-assemble on two half-sites of the polynucleotide to form a tetramer that consists of a dimer of dimers whose stabilization is assured by protein-protein and DNA base-stacking interactions (29). It appears that the ability of Sak to protect genome stability is more "primordial" as the information for self-assembly is all contained in the protein structure without the need for interactions with damaged DNA. This feature may provide Sak with the advantage of being less restricted in its ability to repair DNA and guarantee genome stability. Self-assembly of Sak in toroidal structures raises the interesting possibility of non-chemical signaling between the protein and DNA, possibly through biological quantum entanglement between the electron clouds of toroids of DNA and the

electron clouds on the surface of toroidal Sak (for reference on biological quantum entanglement between electron clouds of nucleic acids, see 30). It is well known that DNA is organized in toroid units within sperm chromatin and in the head of phages (31, 32) and condensation of a constrained DNA molecule into a toroid increases its tension and modifies the electromagnetic properties associated with the distribution of electrical charges on its surface (33). It could then be hypothesized that toroidal structures of DNA and proteins such as Sak may become entangled because of their spatial geometry; this phenomenon would not be dissimilar from the quantum entanglement at the level of the protein tubulin in neuron microtubules that is thought to be at the basis of human consciousness (34). It would also be consistent with the recent paper by Authors from The Netherlands entitled "Is the Fabric of Reality Guided by a Semi-Harmonic, Toroidal Background Field?" (35). It is interesting to notice that DNA itself is endowed with an intrinsic degree of consciousness (36) that obviously does not rely upon quantum entanglement at the level of tubulin. It is also interesting to notice that ancient viruses may have been responsible for the onset of consciousness in humans (37) and, therefore, it is at least theoretically plausible that the intrinsic consciousness of the DNA of viruses and humans may have become entangled at different levels.

Although the concept of quantum entanglement may appear esoteric and distant from the daily routine of biological entities, quantum coherence and entanglement are at work in phenomena such as the origin of life (38), photosynthesis, a process at the basis of today's life on this planet (39), biology of the retina (40), bird navigation in the skies (41), fish communication in the water (42), and human consciousness (for reference in addition to Hameroff et al. (34), see a recent study using Magnetic Resonance Imaging of the human brain (43). It is therefore of interest to consider that each phenomenon of quantum entanglement is associated with formation of a wormhole through the geometry of entanglement (44), a phenomenon that could explain the apparent reversal of direction of time in the experiments of Mothersill et al., a reversal of time described by the Authors as "temporally displaced awareness after the fish become entangled" (42).

Going back to the role of Sak in the context of DNA repair, it is worth noticing that Sak is able to bind RecA and stimulate homologous recombination reactions. Not surprisingly, human RAD52, an evolutionary derivative of Sak, was recently defined "a novel player in DNA repair in cancer and immunodeficiency" and was attributed a tumor suppressor function (45). These functions of Sak/RAD52 are consistent with a recent clinical observation in a case of multiple myeloma (19). It is also worth noticing that RAD52 was demonstrated to suppress HIV-1 infection in a manner independent of its ability to repair DNA double strand breaks through homologous recombination (46). Although there are no direct evidences for a role of Sak protein in suppressing retroviral infections, since this activity resides in the DNA-binding and self-interaction domains of RAD52 that are homologous to Sak, it is tempting to speculate that Sak of phage ϕ U36 may also have anti-retroviral activities by binding to retroviral cDNA and suppressing integration of the infecting virus (46). We are not aware if the probiotic yogurt described by Irvine et al. in 2010 (1) contained phages and, in particular, Lactococcus phage ϕ U36; if this were the case, however, the significant positive effects on people living with HIV/AIDS may be attributed also to the anti-retroviral properties of Sak.

Lactococcus phage TUC2009 shows interesting properties as far as detoxification of carcinogenic metals is concerned. It is well known that lactic acid bacteria such as those present in the examined product participate in detoxification of toxins that may contaminate food, examples of which are aflatoxin M1 (47), polycyclic aromatic hydrocarbons (PAHs), heterocyclic amines (HAs) and phthalic acid esters (PAEs) (48). It is also known that other strains present in the product, such as *Streptococcus thermophilus*, protect against toxicity of cadmium, a carcinogenic metal toxicant. Such a protection occurs by reducing the levels of cadmium in blood and ameliorating alterations in the levels of glutathione and malondialdehyde that are associated with cadmium toxicity (49). The presence of phage TUC2009 represents an interesting addition to the detoxification properties of the examined product as they were described in Blythe et al. (12). This is due to increased expression of the gene *cadA* that is about 20-fold higher in uninfected *Lactococcus* than in the bacteria infected by phage TUC2009 (50). This gene codes for a cadmium efflux ATPase and reduced expression following phage infection is associated with intracellular accumulation of cadmium. This effect of phage TUC2009 infection appears to be specific and not a generalized response to lytic phage infection. Thus, infection of *Lactococcus* by another lytic phage, c2, elicited an opposite response as far as expression of *cadA* was concerned resulting in increased transcription of the gene (50). It is tempting to speculate that bacteria infected with phage TUC2009 are more efficient in eliminating cadmium from the human organism as they are unable to expel it otherwise; cadmium would remain bound to bacterial proteins (51) and be eliminated from the organism together with the lysed bacteria.

Streptococcus phage TP-778L may be of interest in the context of the phenomenon designated viral superinfection exclusion. The gene *ltp* of this phage codes for a protein, Ltp, that is a lipoprotein attached to the outside of the cytoplasmic membrane. Ltp has the role of preventing viral superinfections by blocking injection of DNA of the infecting virus into the cytoplasm of the host cell (52). When the lipid-anchor domain is removed, the resulting truncated Ltp works as a broad-spectrum virus-resistance protein in the context of superinfection exclusion (53) and is able to protect the host cell against other, different, lactococcal phage species (54). Superinfection exclusion is mediated by interaction between negatively charged amino acids in the repeat domains of Ltp and the positively charged carboxyl terminus of the Tape Measure Protein (TMP) of superinfecting phages, as it was demonstrated for phage P008 (53). It is worth considering that a similar protein-protein interaction mediated by charged amino acids may be responsible for a conceptually analogous type of viral infection exclusion between *Lactococcus* phage fd13 and Epstein-Barr virus (EBV, see below). We are not aware of interactions between the negatively charged amino acids in the repeat domains of Ltp and the huge number of proteins that, having positively charged sequences, interact with heparin (55). However, considering that positively charged heparin-binding proteins comprise a number of extracellular proteins, growth factors, chemokines, cytokines, enzymes and lipoproteins, it is worth speculating that interaction between these and the exposed negatively charged sequences of phage proteins such as Ltp may have a role in regulating a variety of biological processes.

The complete genome sequence of Lactococcus phage phiLC3 is described in a paper published by Norwegian Authors in 2003 (56). In this paper, the Authors compare the genome of the phage to the genome of its relatives in Lactococci and Streptococci. Of interest is the sequence ATAAAAAATAGGAGAGTAAATG of ORF88 that codes for a holin. Holins are proteins that form oligomers in the cytoplasmic membrane and lead to formation of holes that, together with the action of lysins, lead to cell death. The amino acid sequence coded for by ORF88 of phage phiLC3 shows significant (77%) identity with other holins, namely those of phages TUC2009, TP901-1, and a putative phage of Lactococcus casei. The percentage of identity was calculated over 31 amino acids. Such a significant percentage of identity leads to speculation of a common origin and it is interesting to note that holins perform essential functions also in eukaryotic cells. Two members of the eukaryotic Bcl-2 family, the multi-domain pro-apoptotic Bax and Bak proteins, display holin behavior that is not shared by other members of the Bcl-2 family (57). In eukaryotic cells, Bax and Bak exert their pro-apoptotic function in response to apoptotic stimuli by causing formation of holes in the mitochondrial outer membrane with consequent release of cytochrome c and other proteins into the cytosol to trigger the cascade of caspases (58). Since mitochondria evolutionarily derive from bacteria (59), it is not surprising that proteins able to form holes in bacteria exert the same action in mitochondria. Disruption of apoptosis is associated with the development of cancer, and Bax and Bak function as tumor suppressors thanks to their holin-like activities (60). It is known that phages induce tumor destruction and it was hypothesized that this anti-cancer activity of phages was mediated by interaction with the cells of the immune system, notably, the macrophages (61). Future research will elucidate whether holin-based mechanisms similar to that of tumor suppressors Bax and Bak may also be responsible for phage-induced cancer destruction.

Lactococcus phage fd13 has a receptor binding protein essential for host interaction that shows a significant degree of homology at the amino terminus with a number of other phages, namely bIL170, phi645, phi7, p272 (AF539443), P113G, sk1, jj50, p2, jw30, jw31, jw32, P008, phi936, phi712, and P475. Since all these phages have different host ranges, it is assumed that the amino terminus of the receptor binding protein is conserved and may serve the purpose of non-specific binding to the host cell (62). This leads to the interesting hypothesis of using phages to fight eukaryotic viral infections through protein-protein interactions as it was recently proposed for phage therapy of EBV infection (63). In the case of EBV, and possibly of other human herpes viruses, phages may prevent infectivity thanks to competition between proteins with KGD (Lys-Gly-Asp) motifs encoded by phages and herpes virus proteins required for membrane fusion and virus entry into eukaryotic cells. In the case of EBV, the KGD motifs involved in such a competition are those of in the gp24 head vertex protein of T4-like phages and those in the glycoprotein gHgL of EBV. Lactococcus phage fd13 shows a very conserved DGK sequence at the amino terminus (62) that may be considered "complementary" to KGD motifs of EBV and possibly of other human herpes viruses. The electrostatic interaction between amino acids with opposite charges (K and D) and the hydrophobic interaction between paired G may stabilize the binding of KGD to DGK motifs. Since KGD motifs of EBV mediate the infection of epithelial cells and B lymphocytes, it can be argued that DGK motifs of Lactococcus phages binding to KGD motifs may prevent infection by EBV and other herpes viruses.

Streptococcus phage 2972 shows a peculiar receptor binding protein that is coded for by ORF20. At the carboxyl terminus, this protein contains six collagen-like repeats motifs whose biological function is to provide elasticity and confer stability to the triple helix structure (64). It can be hypothesized that these motifs may interfere with the self-assembly of eukaryotic collagen monomers in fibrillary structures (65). Such a feature may prove interesting in the context multistep carcinogenesis (66) since collagen is actively involved in tumor progression as it constitutes the scaffold of tumor microenvironment and promotes tumor infiltration, angiogenesis, invasion and migration (67). Since phages ingested with a fermented product come in contact with the mucosa of the entire gastrointestinal tract, it may be hypothesized that such an effect may be of interest for prevention and treatment of malignant cell proliferation arising from the epithelium of the digestive tract. It cannot be ruled out, however, that such an effect may occur also at distant sites as discussed below.

The complete genomic sequence of Lactococcus phage DT1 was published in 1999 (68). The sequence of ORF32 that codes for a 26 kDa protein is of particular interest as it comprises an ATP–GTP binding motif A (P-loop). Phosphate-binding (P-loops) are found in ATP and GTP binding proteins (G-proteins). Their primary structure typically consists of a glycine-rich sequence followed by a conserved lysine and a serine or threonine (69). In molecular oncology, mutations in the context of P-loops bear important consequences as they are associated with oncogenes highly represented in human cancers such as the members of the ras gene family that code for signal transducing G-proteins in the same range of molecular weight of the protein coded for by ORF32. Mutants with three extra amino acids inserted in the P-loop of Ras proteins show significantly decreased affinity for GDP that leads to increased preference for GTP binding with increased oncogenic potential. In addition, in these mutants, GTP hydrolysis is drastically reduced thus leading to prolonged permanence of the oncogenic signal (70). About 33 years ago, we demonstrated that G-proteins coded for by oncogenic ras mutants, not only are associated with mitogenic signals that cannot be turned off, but also make the cells responsive to non-physiologic signals that, therefore, assume the role of tumor promoters. In particular, we demonstrated that cells transformed by transfection with the oncogene EJ/T24-H-ras, but not their normal counterpart, were able to couple a muscarinic receptor agonist, carbamylcholine, with calcium influx and polyphosphoinositide metabolism, all hallmarks of mitogenic signaling (71). Presence of a nucleotide-binding P-loop in the protein coded for by ORF32 of phage DT1 opens interesting perspectives in counteracting oncogenesis associated with mutated G-proteins. It can be envisaged that the phage protein acts as a decoy for GTP binding thus depriving the oncogenic protein of its substrate. It may be argued that mitogenic, signal-transducing G-proteins are localized inside cells as they are attached to the internal layer of the membrane through isoprenyl moieties, fatty acyl moieties, and electrostatic interactions (72), and they are therefore inaccessible to phage proteins. Such an argument however has been recently disproved by demonstration that phages are actually capable of penetrating into human cancer cells and remain active inside cells for at least 24h (73). Another argument against a role for phage proteins as tools against molecular carcinogenesis consists in the fact that ingested phages reside in the gastrointestinal tract and would therefore prove irrelevant for cancers arising in other parts of the body. However, this argument was also disproved by observation that in animals and humans, phages translocate from the gut to other organs (74);

this phenomenon, coupled with the ability of phages to penetrate into eukaryotic cells, is probably responsible for the continuous and dynamic virus-prokaryote-eukaryote gene flow (73). As a matter of fact, ingested phages have been found in sera of healthy individuals since 1971 (75). Researchers from the Polish Academy of Sciences demonstrated since 1987 the presence of phages in blood and urine after oral administration of specific phage preparations aimed at treating bacterial infections resistant to antibiotics; no such phages were detected in those patients prior administration, thus confirming that the phages found in blood and urine came from the gut (76). Phages are able to reach blood through different routes of administration including the intranasal route (77). Once in blood, phages are fully active and able to kill pathogenic bacteria; in a recent paper, it was demonstrated that phage phiHP3 was able to infect, lyse and ultimately kill extra-intestinal pathogenic *Escherichia coli* (ExPEC), a leading cause of bloodstream infections, when present in human blood together with metals such as iron, magnesium and calcium (78).

Lactococcus lactis bacteriophage r1t was studied in detail as far as regulation of gene expression in responses to an anti-tumor chemotherapeutic agent, Mitomycin C, was concerned (79). The chromosomal region of interest of the phage comprises two genes, *rro*, that codes for the phage repressor, and *tec*. It was demonstrated that Mitomycin C, an agent that promotes the switch of r1t from the lysogenic to the lytic life cycle, increased 70-fold the expression of *tec* (79). These results may bear relevance in the context of counteracting the side effects of Mitomycin C chemotherapy. It is known that Mitomycin C leads to oxidative DNA damage and decreases global DNA methylation in a sex-specific pattern in mice; it is also known that most of the changes induced by chemotherapy in the pre-frontal cortex of female mice are similar to those occurring during the brain's ageing (80). Considering the effects of Mitomycin C on phage r1t gene expression, it could be hypothesized that chemotherapy also alters the balance between phages and *Lactococci* in the microbiota, with consequences on the functions regulated by the microbiota and, in particular, on the immune system. Stimulation of lytic effects by Mitomycin C should then be taken into account, and strategies to support the *Lactococci* population could be implemented with the goal of counteracting the increased lethality of phages such as r1t.

Lactococcus phage CB19 belongs to a group of phylogenetically related heat-resistant phages that comprises P1532, SL4, CB13, and CB20. These phages show a remarkable resistance to heat and remain infectious after heat treatment at 80°C for 5 min (81). Molecular characterization of heat-resistant mutants of phage CB14, a related phage that infects the same host as CB19, suggests that resistance to heat is due to the amino acid sequence of TMP, a structural protein within the phage tail. The size of this protein in CB19 is 996 amino acids that is the same size of the other heat-resistant phages SL4, CB13, and CB20, whereas the size of the protein in heat-sensitive, wild-type CB14 is 999. The size of the heat-resistant mutants of CB14 is, however, 959 (81). These data seem to indicate that shorter TMPs are associated with resistance to heat. Such an interpretation is corroborated by evidence that phage P1532, heat-stable up to 90°C, shows an even shorter protein composed by 916 amino acids. TMPs of phages infecting *Lactococcus* strains have hydrophobic regions that assemble in transmembrane-spanning domains that serve different functions for phage infectivity including

the recruitment of chaperones (82). These features, associated with heat-stability as it is the case for phage CB19, may represent an interesting starting point to harness the power of phage-derived, heat-stable proteins to interact with membrane-spanning receptors involved in mitogenic signal transduction. For example, phage-derived heat-stable proteins with hydrophobic domains could interact with receptors such as the Epidermal Growth Factor Receptor that is coupled with intracellular polyphosphoinositide mitogenic signaling as we demonstrated in 1988 (83). Thanks to the heat resistance of phage CB19, such an approach would be particularly indicated in combination with anti-cancer hyperthermia (84).

Streptococcus phages Sfi11 and Sfi19 are two phage types that, although related, are significantly different since they infect different strains of *Streptococcus thermophilus* and have different amino acid composition and tail morphology with Sfi11 showing thinner tails in comparison with Sfi19 (85). Both phages show a number of homologies with *Streptococcus thermophilus* phage TP-J34. Of particular speculative interest for its implications in cancer is the homology between ORF35 of TP-J34 and gp53 of Sfi11 with 100% match identity (53). gp53 is a putative transcription regulator (86). Since a transcription regulator is, by definition, a protein able to interact with DNA, it is tempting to speculate that a transcription regulator may interact also with p53, either at the DNA or at the protein level. Indirect support for this hypothesis comes from observation that peptides isolated from phage display libraries are able to bind human and murine p53 (87). It can be speculated that interaction between gp53 and p53 may restore transcriptional activity of mutant p53; this could be a promising strategy to harness the potential of p53 in protecting cells from carcinogenesis through cell-cycle arrest, senescence, and apoptosis (88).

Conclusions

Phages have been used in therapy of human diseases for more than hundred years, that is soon after their discovery in 1915, when it was enthusiastically thought that they could cure almost any disease (21, 89). Although phage therapy is only now being rediscovered in Western countries (66), it is worth noticing that pharmacies in the country of Georgia and in the Russian Federation have been selling commercial phage cocktails for decades as they belong to the armamentarium of common practitioners (90). In the pre-antibiotic era, phages were conceived as means to kill pathogenic bacteria according to the principle of "My enemy's enemy is my friend" (91), but now it is accepted that they may be helpful in a number of diseases ranging from cancer (92) to autism (93) as they are able to bypass anatomical and physiological barriers and have been found in human body's compartments that were previously considered purely sterile (94). It is also worth considering that many of the biological effects of phages are mediated by their interactions with the immune system. For example, it has been demonstrated since 2009 that tumor-specific phages induce tumor destruction through activation of Tumor-Associated Macrophages as they promote a switch from a tumor-promoting M2-polarized microenvironment to a more M1-polarized milieu (61). This feature of phages is of particular interest when immunotherapies for cancers involving macrophage stimulation are considered (11). Thus, stimulation of macrophages in tumors in the absence of tools that direct them toward an M1 phenotype may lead to counterproductive effects since

Tumor-Associated Macrophages of the M2 phenotype are known to promote tumor proliferation and to be associated with a poor prognosis in numerous cancers (95).

Although phage therapy has never been discontinued in Eastern Europe, in the Western world phage therapy faces regulatory obstacles that limit its diffusion. For example, the Food and Drug Administration of the USA classifies phages within the category of "biologics," a category that comprises anything derived from biology and not from chemical synthesis such as, for example, blood products, antibodies, proteins or viruses that may prove efficient in treating specific diseases. Since biologics are more complex than chemically synthesized small molecule drugs, contain more than one single molecule, may have variable activity, may contain components exerting other functions, and have more complex pharmacokinetics, their regulation and approval are much more challenging (78). All these hindrances are well summarized by the Belgian Author Fauconnier who, in April 2019, wrote "After decades of disregard in the Western world, phage therapy is witnessing a return of interest. However, the pharmaceutical legislation that has since been implemented is basically designed for regulating industrially-made pharmaceuticals, devoid of any patient customization and intended for large-scale distribution. ... The repeated appeal for a dedicated regulatory framework has not been heard by the European legislature, which, in this matter, features a strong resistance to change despite the precedent of the unhindered implementation of advanced therapy medicinal product (ATMPs) regulation. It is acknowledged that in many aspects, phage therapy medicinal products are quite unconventional pharmaceuticals, and likely this lack of conformity to the canonical model hampered the development of a suitable regulatory pathway. However, the regulatory approaches of countries where phage therapy traditions and practice have never been abandoned are now being revisited by some Western countries, opening new avenues for phage therapy regulation" (96).

These considerations, however, may not apply to phages already and constitutively present in alimentary matrices. We propose that phages naturally present in fermented products may yield additional benefits as compared to purified phage preparations (90) in a manner analogous to that observed for probiotic yogurts vs encapsulated probiotics (1, 3). Just like probiotics support the immune system in a much more efficient manner when in their environment, meaning fermented milk, phages may show the best health-supporting qualities when in their environment, that is, in the milieu where their hosts are present in great numbers. It is of interest to note that the presence of phages does not impede the process of fermentation when the biodiversity of the bacterial strains is elevated as is the case for the product described in this paper where the Axiom Microbiome Array evidenced hundreds of different bacterial strains, with the majority of them pertaining to the kefir grain component of the product. Observing the efficiency of fermentation, it is tempting to speculate that bacteria and phages have reached a point of equilibrium in the microflora of the kefir grains and are able to co-exist. It is also tempting to speculate that this naturally achieved equilibrium may favor a sort of entanglement with the human microbiota, a microbiota naturally rich in phages (97). In conclusion, we feel that the answer to the question posed by the article in Science provocatively entitled "Does a sea of viruses inside our body help keep us healthy?" is definitely positive (98).

References

1. Irvine SL, Hummelen R, Hekmat S, Looman CW, Habbema JD, Reid G. Probiotic yogurt consumption is associated with an increase of CD4 count among people living with HIV/AIDS. *J Clin Gastroenterol*. 2010 Oct;44(9):e201-5. doi: 10.1097/MCG.0b013e3181d8fba8.
2. Hemsworth JC, Hekmat S, Reid G. Micronutrient supplemented probiotic yogurt for HIV-infected adults taking HAART in London, Canada. *Gut Microbes*. 2012 Sep-Oct;3(5):414-9. Epub 2012 Jul 24.
3. Hummelen R, Changalucha J, Butamanya NL, Koyama TE, Cook A, Habbema JD, Reid G. Effect of 25 weeks probiotic supplementation on immune function of HIV patients. *Gut Microbes*. 2011 Mar-Apr;2(2):80-5. Epub 2011 Mar 1.
4. Ebner J, Aşçı Arslan A, Fedorova M, Hoffmann R, Küçükçetin A, Pischetsrieder M. Peptide profiling of bovine kefir reveals 236 unique peptides released from caseins during its production by starter culture or kefir grains. *J Proteomics*. 2015 Mar 18;117:41-57. doi: 10.1016/j.jprot.2015.01.005. Epub 2015 Jan 19.
5. Otieno DO, Shah NP. Endogenous beta-glucosidase and beta-galactosidase activities from selected probiotic micro-organisms and their role in isoflavone biotransformation in soymilk. *J Appl Microbiol*. 2007 Oct;103(4):910-7.
6. Nishiyama K, Yamamoto Y, Sugiyama M, Takaki T, Urashima T, Fukiya S, Yokota A, Okada N, Mukai T. *Bifidobacterium bifidum* Extracellular Sialidase Enhances Adhesion to the Mucosal Surface and Supports Carbohydrate Assimilation. *MBio*. 2017 Oct 3;8(5). pii: e00928-17. doi: 10.1128/mBio.00928-17.
7. Pacini S, Punzi T, Morucci G, Ruggiero M. Macrophages of the mucosa-associated lymphoid tissue (mALT) as key elements of the immune response to vitamin D binding protein-macrophage activating factor. *IJAE Vol. 116, n. 1. S: 136, 2011.*
8. Delanghe JR, Speeckaert R, Speeckaert MM. Behind the scenes of vitamin D binding protein: more than vitamin D binding. *Best Pract Res Clin Endocrinol Metab*. 2015 Oct;29(5):773-86. doi: 10.1016/j.beem.2015.06.006. Epub 2015 Jul 2.
9. Saburi E, Saburi A, Ghanei M. Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside. *Caspian J Intern Med*. 2017 Fall;8(4):228-238. doi: 10.22088/cjim.8.4.228.
10. Ward E, Smith R, Branca JJV, Noakes D, Morucci G and Thyer L. Clinical experience of cancer immunotherapy integrated with oleic acid complexed with de-glycosylated vitamin D binding protein. *Am J Immunol* 2014, 10 (1): 23-32. doi: 10.3844/ajisp.2014.23.32.

11. Ruggiero M, Ward E, Smith R, Branca JJ, Noakes D, Morucci G, Taubmann M, Thyer L, Pacini S. Oleic Acid, deglycosylated vitamin D-binding protein, nitric oxide: a molecular triad made lethal to cancer. *Anticancer Res.* 2014 Jul;34(7):3569-78.
12. Blythe J, Ruggiero M, Pacini S. Intermittent fasting and probiotic yogurt consumption are associated with reduction of serum alpha-N-acetylgalactosaminidase and increased urinary excretion of lipophilic toxicants. *Madridge J Immunol.* 2017; 1(1): 23-27.
doi: 10.18689/mjim-1000107.
13. Thissen JB, Be NA, McLoughlin K, Gardner S, Rack PG, Shapero MH, Rowland RRR, Slezak T, Jaing CJ. Axiom Microbiome Array, the next generation microarray for high-throughput pathogen and microbiome analysis. *PLoS ONE* 2019, 14(2): e0212045.
14. Kiliç AO, Pavlova SI, Ma WG, Tao L. Analysis of Lactobacillus phages and bacteriocins in American dairy products and characterization of a phage isolated from yogurt. *Appl Environ Microbiol.* 1996 Jun;62(6):2111-6.
15. Foschino R, Venturelli E, Picozzi C. Isolation and characterization of a virulent Lactobacillus sanfranciscensis bacteriophage and its impact on microbial population in sourdough. *Curr Microbiol.* 2005 Dec;51(6):413-8. Epub 2005 Oct 15.
16. Pannaraj PS, Ly M, Cerini C, Saavedra M, Aldrovandi GM, Saboory AA, Johnson KM, Pride DT. Shared and Distinct Features of Human Milk and Infant Stool Viromes. *Front Microbiol.* 2018 Jun 1;9:1162. doi: 10.3389/fmicb.2018.01162.
17. Fernández L, Escobedo S, Gutiérrez D, Portilla S, MartínezOrCID B, García P, Rodríguez A. Bacteriophages in the Dairy Environment: From Enemies to Allies. *Antibiotics* 2017, 6(4), 27.
18. Carding SR, Davis N, Hoyles L. Review article: the human intestinal virome in health and disease. *Aliment Pharmacol Ther.* 2017 Nov;46(9):800-815. Epub 2017 Sep 4.
doi: 10.1111/apt.14280.
19. Antonucci N, Pacini S, Ruggiero M. Use of an Extremely Biodiverse Probiotic and a Supplement Based on Microbial Chondroitin Sulfate is Associated with a Significant Decrease of Serum Free Kappa Light Chains as well as a Trend Toward Normalization of Kappa/Lambda Ratio and of Plasma Cell Bone Marrow Infiltration in a Case of Multiple Myeloma. *Am J Immunol.* 2019, 15; 5-9. doi: 10.3844/ajisp.2019.5.9.
20. Adriaenssens EM, Edwards R, Nash JHE, Mahadevan P, Seto D, Ackermann HW, Lavigne R, Kropinski AM. Integration of genomic and proteomic analyses in the classification of the Siphoviridae family. *Virology.* 2015 Mar;477:144-154. Epub 2014 Nov 14.
doi: 10.1016/j.virol.2014.10.016.

21. Twort FW. Further Investigations on the Nature of Ultra-Microscopic Viruses and their Cultivation. *J Hyg (Lond)*. 1936 Jun;36(2):204-35. doi: 10.1017/s0022172400043606.
22. Gindin M, Febvre HP, Rao S, Wallace TC, Weir TL. Bacteriophage for Gastrointestinal Health (PHAGE) Study: Evaluating the Safety and Tolerability of Supplemental Bacteriophage Consumption. *J Am Coll Nutr*. 2019 Jan;38(1):68-75. doi: 10.1080/07315724.2018.1483783. Epub 2018 Aug 29.
23. Mahony J, Martel B, Tremblay DM, Neve H, Heller KJ, Moineau S, van Sinderen D. Identification of a new P335 subgroup through molecular analysis of lactococcal phages Q33 and BM13. *Appl Environ Microbiol*. 2013 Jul;79(14):4401-9. doi: 10.1128/AEM.00832-13. Epub 2013 May 10.
24. Nelson I, Higuera A, Huycke MM. Enterococcal Disease, Epidemiology, and Implications for Treatment. Gilmore MS, Clewell DB, Ike Y, et al., editors. Boston: Massachusetts Eye and Ear Infirmary; 2014.
25. Dicks LMT, Mikkelsen LS, Brandsborg E, Marcotte H. Clostridium difficile, the Difficult "Kloster" Fuelled by Antibiotics. *Curr Microbiol*. 2019 Jun;76(6):774-782. doi: 10.1007/s00284-018-1543-8. Epub 2018 Aug 6.
26. Ploquin M, Bransi A, Paquet ER, Stasiak AZ, Stasiak A, Yu X, Cieslinska AM, Egelman EH, Moineau S, Masson JY. Functional and structural basis for a bacteriophage homolog of human RAD52. *Curr Biol*. 2008 Aug 5;18(15):1142-6. doi: 10.1016/j.cub.2008.06.071. Epub 2008 Jul 24.
27. Li Z1, Guo Y, Zhou L, Ge Y, Wei L, Li L, Zhou C, Wei J, Yuan Q, Li J, Yang M. Association of a functional RAD52 genetic variant locating in a miRNA binding site with risk of HBV-related hepatocellular carcinoma. *Mol Carcinog*. 2015 Sep;54(9):853-8. doi: 10.1002/mc.22156. Epub 2014 Apr 11.
28. Nguyen D, Liao W, Zeng SX, Lu H. Reviving the guardian of the genome: Small molecule activators of p53. *Pharmacol Ther*. 2017 Oct;178:92-108. doi: 10.1016/j.pharmthera.2017.03.013. Epub 2017 Mar 27.
29. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, Shaked Z. Structural basis of DNA recognition by p53 tetramers. *Mol Cell*. 2006 Jun 23;22(6):741-53.
30. Rieper E, Anders J, Vedral V. Quantum entanglement between the electron clouds of nucleic acids in DNA. <https://arxiv.org/abs/1006.4053>.
31. Brewera LR. Deciphering the structure of DNA toroids. *Integrative Biol*. 2011, 5. doi: 10.1039/C0IB00128G.

32. Leforestier A, Livolant F. Structure of toroidal DNA collapsed inside the phage capsid. PNAS June 9, 2009 106 (23) 9157-9162; <https://doi.org/10.1073/pnas.0901240106>.
33. Blank M, Goodman R. DNA is a fractal antenna in electromagnetic fields. Int J Radiat Biol. 2011 Apr;87(4):409-15. doi: 10.3109/09553002.2011.538130. Epub 2011 Feb 28.
34. Hameroff SR, Craddock TJ, Tuszyński JA. Quantum effects in the understanding of consciousness. J Integr Neurosci. 2014 Jun;13(2):229-52. doi: 10.1142/S0219635214400093.
35. Meijer DKF, Geesink JH. Is the Fabric of Reality Guided by a Semi-Harmonic, Toroidal Background Field? Symbiosis, 2018, 8; 1-15.
36. Grandy JK. The DNA molecule is autopoietic, dynamic, evolving, and a form of consciousness. International Journal of Arts & Sciences. CD-ROM. ISSN: 1944-6934: 4(20):7–30 (2011) Copyright 2011 by International Journal.org.
37. Pastuzyn ED, Day CE, Kearns RB, Kyrke-Smith M, Taibi AV, McCormick J, Yoder N, Belnap DM, Erlendsson S, Morado DR, Briggs JAG, Feschotte C, Shepherd JD. The Neuronal Gene Arc Encodes a Repurposed Retrotransposon Gag Protein that Mediates Intercellular RNA Transfer. Cell. 2018 Jan 11;172(1-2):275-288.e18. doi: 10.1016/j.cell.2017.12.024.
38. Tamulis A, Grigalavicius M. Quantum entanglement in photoactive prebiotic systems. Syst Synth Biol. 2014 Jun;8(2):117-40. doi: 10.1007/s11693-014-9138-6. Epub 2014 Mar 25.
39. Smyth C, Oblinsky DG, Scholes GD. B800-B850 coherence correlates with energy transfer rates in the LH2 complex of photosynthetic purple bacteria. Phys Chem Chem Phys. 2015 Dec 14;17(46):30805-16. doi: 10.1039/c5cp00295h.
40. Sia PI, Luiten AN, Stace TM, Wood JP, Casson RJ. Quantum biology of the retina. Clin Exp Ophthalmol. 2014 Aug;42(6):582-9. doi: 10.1111/ceo.12373. Epub 2014 Aug 7.
41. Pauls JA, Zhang Y, Berman GP, Kais S. Quantum coherence and entanglement in the avian compass. Phys Rev E Stat Nonlin Soft Matter Phys. 2013 Jun;87(6):062704. Epub 2013 Jun 11.
42. Mothersill C, Smith R, Wang J, Rusin A, Fernandez-Palomo C, Fazzari J, Seymour C. Biological Entanglement-Like Effect After Communication of Fish Prior to X-Ray Exposure. Dose Response. 2018 Feb 15;16(1):1559325817750067. doi: 10.1177/1559325817750067. eCollection 2018 Jan-Mar.
43. Kerskens C, López Pérez D. Evidence of quantum consciousness in evoked zero-spin echoes. bioRxiv preprint first posted online Nov. 15, 2017; doi: <http://dx.doi.org/10.1101/219931>
44. Sonner J. Holographic Schwinger effect and the geometry of entanglement. Phys Rev Lett. 2013 Nov 22;111(21):211603. Epub 2013 Nov 20.

45. Ghosh S, Hönscheid A, Dückers G, Ginzl S, Gohlke H, Gombert M, et al. Human RAD52 – a novel player in DNA repair in cancer and immunodeficiency. *Haematologica*. 2017 Feb; 102(2): e69–e72. doi: 10.3324/haematol.2016.155838.
46. Lau A, Kanaar R, Jackson SP, O'Connor MJ. Suppression of retroviral infection by the RAD52 DNA repair protein. *EMBO J*. 2004 Aug 18;23(16):3421-9. Epub 2004 Aug 5.
47. Fashandi HM, Abbasi R, Khaneghah AM. The detoxification of aflatoxin M1 by *Lactobacillus acidophilus* and *Bifidobacterium* spp.: A review. *J Food Process Preserv*. 2018, Sept. 27, <https://doi.org/10.1111/jfpp.13704>.
48. Lili Z, Junyan W, Hongfei Z, Baoqing Z, Bolin Z. Detoxification of cancerogenic compounds by lactic acid bacteria strains. *Crit Rev Food Sci Nutr*. 2018;58(16):2727-2742. doi: 10.1080/10408398.2017.1339665. Epub 2017 Oct 20.
49. G Allam N, M Ali EM, Shabanna S, Abd-Elrahman E. Protective Efficacy of *Streptococcus Thermophilus* Against Acute Cadmium Toxicity in Mice. *Iran J Pharm Res*. 2018 Spring;17(2):695-707.
50. Ainsworth S, Zomer A, Mahony J, van Sinderen D. Lytic infection of *Lactococcus lactis* by bacteriophages Tuc2009 and c2 triggers alternative transcriptional host responses. *Appl Environ Microbiol*. 2013 Aug;79(16):4786-98. doi: 10.1128/AEM.01197-13. Epub 2013 May 31.
51. Binet MR, Ma R, McLeod CW, Poole RK. Detection and characterization of zinc- and cadmium-binding proteins in *Escherichia coli* by gel electrophoresis and laser ablation-inductively coupled plasma-mass spectrometry. *Anal Biochem*. 2003 Jul 1;318(1):30-8.
52. Sun X, Göhler A, Heller KJ, Neve H. The *ltp* gene of temperate *Streptococcus thermophilus* phage TP-J34 confers superinfection exclusion to *Streptococcus thermophilus* and *Lactococcus lactis*. *Virology*. 2006 Jun 20;350(1):146-57. Epub 2006 Apr 27.
53. Ali Y, Koberg S, Heßner S, Sun X, Rabe B, Back A, et al. Temperate *Streptococcus thermophilus* phages expressing superinfection exclusion proteins of the *Ltp* type. *Front Microbiol*. 2014; 5: 98. Published online 2014 Mar 13. doi: 10.3389/fmicb.2014.00098.
54. Bebeacua C, Lorenzo Fajardo JC, Blangy S, Spinelli S, Bollmann S, Neve H, et al. X-ray structure of a superinfection exclusion lipoprotein from phage TP-J34 and identification of the tape measure protein as its target. *Mol Microbiol*. 2013 Jul;89(1):152-65. doi: 10.1111/mmi.12267. Epub 2013 Jun 7.
55. Peysselon F, Ricard-Blum S. Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis. *Matrix Biol*. 2014 Apr;35:73-81. doi: 10.1016/j.matbio.2013.11.001. Epub 2013 Nov 16.

56. Blatny JM, Godager L, Lunde M, Nes IF. Complete genome sequence of the *Lactococcus lactis* temperate phage phiLC3: comparative analysis of phiLC3 and its relatives in lactococci and streptococci. *Virology*, 2004, 318(1):231-244. <https://doi.org/10.1016/j.virol.2003.09.019>.
57. Pang X, Moussa SH, Targy NM, Bose JL, George NM, Gries C, et al. Active Bax and Bak are functional holins. *Genes Dev.* 2011 Nov 1; 25(21): 2278–2290. doi: 10.1101/gad.171645.111.
58. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. *Cell.* 2003 Feb 21;112(4):481-90.
59. Gray MW. Mitochondrial Evolution. *Cold Spring Harb Perspect Biol.* 2012 Sep; 4(9): a011403. doi: 10.1101/cshperspect.a011403.
60. Degenhardt K, Chen G, Lindsten T, White E. BAX and BAK mediate p53-independent suppression of tumorigenesis. *Cancer Cell.* 2002 Sep;2(3):193-203.
61. Eriksson F, Tsagozis P, Lundberg K, Parsa R, Mangsbo SM, Persson MA, Harris RA, Pisa P. Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages. *J Immunol.* 2009 Mar 1;182(5):3105-11. doi: 10.4049/jimmunol.0800224.
62. Dupont K, Janzen T, Vogensen FK, Josephsen J, Stuer-Lauridsen B. Identification of *Lactococcus lactis* Genes Required for Bacteriophage Adsorption. *Appl Environ Microbiol.* 2004 Oct; 70(10): 5825–5832. doi: 10.1128/AEM.70.10.5825-5832.2004.
63. Górski A, Międzybrodzki R, Jończyk-Matysiak E, Weber-Dąbrowska B, Bagińska N, Borysowski J. Perspectives of Phage–Eukaryotic Cell Interactions to Control Epstein–Barr Virus Infections. *Front Microbiol.* 2018; 9: 630. Published online 2018 Apr 3. doi: 10.3389/fmicb.2018.00630.
64. Lévesque C, Duplessis M, Labonté J, Labrie S, Fremaux C, Tremblay D, Moineau S. Genomic organization and molecular analysis of virulent bacteriophage 2972 infecting an exopolysaccharide-producing *Streptococcus thermophilus* strain. *Appl Environ Microbiol.* 2005 Jul;71(7):4057-68.
65. Zhu J, Kaufman LJ. Collagen I Self-Assembly: Revealing the Developing Structures that Generate Turbidity. *Biophys J.* 2014 Apr 15; 106(8): 1822–1831. doi: 10.1016/j.bpj.2014.03.011.
66. Rehman S, Ali Z, Khan M, Bostan N, Naseem S. The dawn of phage therapy. *Rev Med Virol.* 2019 Jul;29(4):e2041. doi: 10.1002/rmv.2041. Epub 2019 May 3.
67. Fang M, Yuan J, Peng C, Li Y. Collagen as a double-edged sword in tumor progression. *Tumour Biol.* 2014 Apr;35(4):2871-82. doi: 10.1007/s13277-013-1511-7. Epub 2013 Dec 15.

68. Tremblay DM, Moineau S. Complete genomic sequence of the lytic bacteriophage DT1 of *Streptococcus thermophilus*. *Virology*. 1999 Mar 1;255(1):63-76.
69. Saraste M, Sibbald PR, Wittinghofer A. The P-loop--a common motif in ATP- and GTP-binding proteins. *Trends Biochem Sci*. 1990 Nov;15(11):430-4.
70. Klockow B, Ahmadian MR, Block C, Wittinghofer A. Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling. *Oncogene*, 2000; 19, 5367-5376.
71. Chiarugi VP, Pasquali F, Vannucchi S, Ruggiero M. Point-mutated p21ras couples a muscarinic receptor to calcium channels and polyphosphoinositide hydrolysis. *Biochem Biophys Res Commun*. 1986 Dec 15;141(2):591-9.
72. Vögler O, Barceló JM, Ribas C, Escribá PV. Membrane interactions of G proteins and other related proteins. *Biochim Biophys Acta*. 2008 Jul-Aug;1778(7-8):1640-52. doi: 10.1016/j.bbamem.2008.03.008. Epub 2008 Mar 19.
73. Lehti TA, Pajunen MI, Skog MS, Finne J. Internalization of a polysialic acid-binding *Escherichia coli* bacteriophage into eukaryotic neuroblastoma cells. *Nat Commun*. 2017 Dec 4;8(1):1915. doi: 10.1038/s41467-017-02057-3.
74. Górski A, Ważna E, Dąbrowska BW, Dąbrowska K, Świtła-Jeleń K, Międzybrodzki R. Bacteriophage translocation. *FEMS Immunology & Medical Microbiology*, Volume 46, Issue 3, April 2006, Pages 313–319, <https://doi.org/10.1111/j.1574-695X.2006.00044>.
75. Parent K, Wilson ID. Mycobacteriophage in Crohn's disease. *Gut*. 1971 Dec; 12(12): 1019–1020. doi: 10.1136/gut.12.12.1019.
76. Weber-Dabrowska B, Dabrowski M, Slopek S. Studies on bacteriophage penetration in patients subjected to phage therapy. *Arch Immunol Ther Exp (Warsz)*. 1987;35(5):563-8.
77. Bogovazova GG, Voroshilova NN, Bondarenko VM. [The efficacy of *Klebsiella pneumoniae* bacteriophage in the therapy of experimental *Klebsiella* infection]. *Zh Mikrobiol Epidemiol Immunobiol*. 1991 Apr;(4):5-8.
78. Ma L, Green SI, Trautner BW, Ramig RF, Maresso AW. Metals Enhance the Killing of Bacteria by Bacteriophage in Human Blood. *Sci Rep*. 2018 Feb 2;8(1):2326. doi: 10.1038/s41598-018-20698-2.
79. Nauta A, van Sinderen D, Karsens H, Smit E, Venema G, Kok J. Inducible gene expression mediated by a repressor-operator system isolated from *Lactococcus lactis* bacteriophage r1t. *Mol Microbiol*. 1996 Mar;19(6):1331-41.

80. Kovalchuk A, Rodriguez-Juarez R, Ilnytskyy Y, Byeon B, Shpyleva S, Melnyk S, et al. Sex-specific effects of cytotoxic chemotherapy agents cyclophosphamide and mitomycin C on gene expression, oxidative DNA damage, and epigenetic alterations in the prefrontal cortex and hippocampus – an aging connection. *Aging (Albany NY)*. 2016 Apr; 8(4): 697–708. Published online 2016 Mar 30. doi: 10.18632/aging.100920.
81. Geagea H, Labrie SJ, Subirade M, Moineau S. The Tape Measure Protein Is Involved in the Heat Stability of *Lactococcus lactis* Phages. *Appl Environ Microbiol*. 2018 Feb 1; 84(3): e02082-17. Published online 2018 Jan 17. Prepublished online 2017 Nov 17. doi: 10.1128/AEM.02082-17
82. Mahony J, Alqarni M, Stockdale S, Spinelli S, Feyereisen M, Cambillau C, van Sinderena D. Functional and structural dissection of the tape measure protein of lactococcal phage TP901-1. *Sci Rep*. 2016; 6: 36667. Published online 2016 Nov 8. doi: 10.1038/srep36667.
83. Pierce JH, Ruggiero M, Fleming TP, Di Fiore PP, Greenberger JS, Varticovski L, Schlessinger J, Rovera G, Aaronson SA. Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells. *Science*. 1988 Feb 5;239(4840):628-31.
84. Oei AL, Vriend LEM, Krawczyk PM, Horsman MR, Franken NAP, Crezee J. Targeting therapy-resistant cancer stem cells by hyperthermia. *Int J Hyperthermia*. 2017 Jun;33(4):419-427. doi: 10.1080/02656736.2017.1279757. Epub 2017 Feb 2.
85. Lucchini S, Desiere F, Brüssow H. The structural gene module in *Streptococcus thermophilus* bacteriophage phi Sfi11 shows a hierarchy of relatedness to Siphoviridae from a wide range of bacterial hosts. *Virology*. 1998 Jun 20;246(1):63-73.
86. Kilcher S, Loessner MJ, Klumpp J. *Brochothrix thermosphacta* bacteriophages feature heterogeneous and highly mosaic genomes and utilize unique prophage insertion sites. *J Bacteriol*. 2010 Oct;192(20):5441-53. doi: 10.1128/JB.00709-10. Epub 2010 Aug 13.
87. Daniels DA, Lane DP. The characterisation of p53 binding phage isolated from phage peptide display libraries. *J Mol Biol*. 1994 Nov 4;243(4):639-52.
88. Binayke A, Mishra S, Suman P, Das S, Chander H. Awakening the "guardian of genome": reactivation of mutant p53. *Cancer Chemother Pharmacol*. 2019 Jan;83(1):1-15. doi: 10.1007/s00280-018-3701-x. Epub 2018 Oct 15.
89. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST. Phage therapy in clinical practice: treatment of human infections. *Curr Pharm Biotechnol*. 2010 Jan;11(1):69-86.
90. Villarroel J, Larsen MV, Kilstrup M, Nielsen M. Metagenomic Analysis of Therapeutic PYO Phage Cocktails from 1997 to 2014. *Viruses*. 2017 Nov 3;9(11). pii: E328. doi: 10.3390/v9110328.

91. Bradbury J. "My enemy's enemy is my friend." Using phages to fight bacteria. *Lancet*. 2004 Feb 21;363(9409):624-5.
92. Budynek P, Dabrowska K, Skaradziński G, Górski A. Bacteriophages and cancer. *Arch Microbiol*. 2010 May;192(5):315-20. doi: 10.1007/s00203-010-0559-7. Epub 2010 Mar 16.
93. Kang DW, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. *Microbiome*. 2017; 5: 10. Published online 2017 Jan 23. doi: 10.1186/s40168-016-0225-7.
94. Huh H, Wong S, St Jean J, Slavcev R. Bacteriophage interactions with mammalian tissue: Therapeutic applications. *Adv Drug Deliv Rev*. 2019 Jan 17. pii: S0169-409X(19)30003-1. doi: 10.1016/j.addr.2019.01.003. [Epub ahead of print].
95. Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, et al. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. *Gastric Cancer*. 2016 Oct;19(4):1052-1065. doi: 10.1007/s10120-015-0579-8. Epub 2015 Nov 30.
96. Fauconnier A. Phage Therapy Regulation: From Night to Dawn. *Viruses*. 2019 Apr 17;11(4). pii: E352. doi: 10.3390/v11040352.
97. Paule A, Frezza D, Edeas M. Microbiota and Phage Therapy: Future Challenges in Medicine. *Med Sci (Basel)*. 2018 Oct 5;6(4). pii: E86. doi: 10.3390/medsci6040086.
98. Guglielmi G. Does a sea of viruses inside our body help keep us healthy? *Science*, 2017. doi:10.1126/science.aar5441

Acknowledgements

The Authors wish to thank Dr. Jerry Blythe for critically reviewing the manuscript and suggesting changes to improve intelligibility.

Authors' Contributions

Stefania Pacini, MD, PhD and Marco Ruggiero, MD, PhD contributed equally to this paper.

Disclosures

Marco Ruggiero is the founder and CEO of Silver Spring Sagl, the company producing the fermented product described in this paper. Stefania Pacini works as Quality Control Responsible Person for Silver Spring Sagl. Both had no prior knowledge of the results of the Axiom Microbiome Array that was independently performed by Eurofins Microbiology Laboratories Inc. (New Berlin Wisconsin, USA) on a commercially available lot as part of the company's quality controls.

Advisory

No information in this paper is intended or implied to be a substitute for professional medical advice, diagnosis or treatment.

Ethics

This article is original and contains material that has not been submitted or published in any journal.